STARPHARMA HLDG.SP.ADR/10 (F:PQ6A) — Stock Price
STARPHARMA HLDG.SP.ADR/10 (F:PQ6A) is currently trading at €4.40 EUR, down 3.51% today. Over the past 52 weeks, shares have ranged between €0.40 and €4.56. This page tracks STARPHARMA HLDG.SP.ADR/10's live share price on the F exchange, its daily price and volume history, and — where reported — its income statement, balance sheet, cash flow statement, and earnings history. For company valuation and market capitalisation context, see how much is STARPHARMA HLDG.SP.ADR/10 worth.
STARPHARMA HLDG.SP.ADR/10 (PQ6A) Stock Price Chart — Daily History & Trading Volume
The chart below tracks STARPHARMA HLDG.SP.ADR/10's daily closing share price and trading volume on the F exchange over the past year, giving a clear view of recent price momentum and liquidity.
STARPHARMA HLDG.SP.ADR/10 Income Statement — Revenue, Profit & Earnings by Year
STARPHARMA HLDG.SP.ADR/10's annual income statement shows how revenue converts into profit each fiscal year, including gross profit, operating income, EBITDA, and net income.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Revenue | €4.91 Million | €8.29 Million | €2.94 Million | €4.68 Million |
| Cost of Revenue | €1.22 Million | €632.00K | €1.12 Million | €2.78 Million |
| Gross Profit | €3.69 Million | €7.66 Million | €1.82 Million | €1.91 Million |
| Research & Development | €8.36 Million | €10.05 Million | €11.24 Million | €11.68 Million |
| SG&A | €3.03 Million | €3.57 Million | €3.77 Million | €3.29 Million |
| Total Operating Expenses | — | — | — | — |
| Operating Income | €-12.00 Million | €-10.75 Million | €-18.24 Million | €-17.71 Million |
| EBITDA | — | — | — | — |
| EBIT | — | — | — | — |
| Interest Expense | — | — | — | — |
| Income Before Tax | €-9.99 Million | €-8.16 Million | €-15.64 Million | €-16.15 Million |
| Income Tax Expense | — | — | — | — |
| Net Income | €-9.99 Million | €-8.16 Million | €-15.64 Million | €-16.15 Million |
STARPHARMA HLDG.SP.ADR/10 Balance Sheet — Assets, Liabilities & Shareholder Equity
The balance sheet below summarizes STARPHARMA HLDG.SP.ADR/10's financial position at each fiscal year-end — what it owns (assets), what it owes (liabilities), and the resulting shareholder equity.
| Fiscal Year | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total Assets | €25.42 Million | €36.81 Million | €52.09 Million | €66.17 Million |
| Total Current Assets | €22.56 Million | €32.92 Million | €47.12 Million | €60.66 Million |
| Cash & Equivalents | — | — | — | — |
| Short-term Investments | — | — | — | — |
| Net Receivables | €4.04 Million | €6.09 Million | €7.86 Million | €7.29 Million |
| Inventory | €1.92 Million | €2.41 Million | €2.77 Million | €2.82 Million |
| Property, Plant & Equipment | — | — | — | — |
| Goodwill | — | — | — | — |
| Total Liabilities | €6.42 Million | €8.70 Million | €17.27 Million | €17.78 Million |
| Total Current Liabilities | €5.23 Million | €6.66 Million | €14.47 Million | €10.23 Million |
| Long-term Debt | — | — | — | €4.00 Million |
| Net Debt | — | — | — | — |
| Total Stockholder Equity | €19.00 Million | €28.12 Million | €34.81 Million | €48.39 Million |
| Retained Earnings | €-252.35 Million | €-242.36 Million | €-234.20 Million | €-218.56 Million |
STARPHARMA HLDG.SP.ADR/10 Cash Flow Statement — Operating, Investing & Financing Activities
This cash flow statement breaks down how STARPHARMA HLDG.SP.ADR/10 generates and spends cash across operating, investing, and financing activities each fiscal year, including free cash flow and capital expenditures.
| Fiscal Year |
|---|
| Operating Cash Flow |
| Capital Expenditures |
| Free Cash Flow |
| Investing Cash Flow |
| Financing Cash Flow |
| Dividends Paid |
| Stock-Based Compensation |
| Depreciation |
| Change in Cash |
STARPHARMA HLDG.SP.ADR/10 Earnings History — EPS Actual vs. Analyst Estimates
Track STARPHARMA HLDG.SP.ADR/10's quarterly earnings per share (EPS) against Wall Street estimates, along with the earnings surprise percentage for each reporting period.
| Report Date | EPS Actual | EPS Estimate | Surprise |
|---|---|---|---|
| Feb 24, 2026 | — | — | — |
| Aug 20, 2025 | — | — | — |
| Feb 26, 2025 | — | — | — |
| Oct 30, 2024 | — | — | — |